Disease · MONDO_0005321

Fuchs' endothelial dystrophy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Fuchs' endothelial dystrophy. Diseases, record MONDO_0005321. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005321

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Fuchs' endothelial dystrophy; Open Targets
Open Targets ID: MONDO_0005321; Open Targets
Other names: Dystrophy, Fuch's Endothelial, Dystrophy, Fuchs' Endothelial, Endoepithelial corneal dystrophy, Endothelial Dystrophy, Fuch's, Endothelial Dystrophy, Fuchs', FECD, Fuch Endothelial Dystrophy, Fuch's Endothelial Dystrophy, Fuchs endothelial corneal dystrophy, Fuchs' corneal dystrophy, Fuchs's corneal dystrophy, corneal dystrophy, Fuchs endothelial, late hereditary endothelial dystrophy; Open Targets
Disease Ontology: DOID:11555; Disease Ontology
MeSH: D005642; MeSH
NCI Thesaurus: C84721; NCI Thesaurus
Orphanet: ORPHA:98974; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIPASUDIL	CHEMBL3426621	Small molecule	Phase 3	ClinicalTrials.gov	6	6	5	Drugs and targets
NETARSUDIL	CHEMBL4594250	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	4	Drugs and targets
ACETYLCYSTEINE	CHEMBL600	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RIPASUDIL HYDROCHLORIDE DIHYDRATE	CHEMBL4594454	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ELAMIPRETIDE	CHEMBL3833370	Protein	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ROCK1	Rho-associated protein kinase	3	Rho-associated protein kinase inhibitor	Phase 3	https://conductscience.org/library/genes/6093	Drugs and targets
ROCK2	Rho-associated protein kinase	3	Rho-associated protein kinase inhibitor	Phase 3	https://conductscience.org/library/genes/9475	Drugs and targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04498169	A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy	Phase 2	40	2022-09-01	Corneal Edema	NETARSUDIL	Its record names the disease	ClinicalTrials.gov
NCT04051463	Rhopressa for Corneal Edema Associated With Fuchs Dystrophy	Phase 2/3	29	2021-09-24	Fuchs Endothelial Dystrophy	NETARSUDIL	Its record names the disease	ClinicalTrials.gov
NCT02653391	A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)	Phase 1/2	22	2021-09-17	Fuchs' Corneal Endothelial Dystrophy (FCED)	ELAMIPRETIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT06048380	The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery	Phase 3	120		Fuchs' Endothelial Dystrophy, Cataract	RIPASUDIL	Its record names the disease	ClinicalTrials.gov
NCT05826353	A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)	Phase 3	110		Fuchs Endothelial Corneal Dystrophy	RIPASUDIL	Its record names the disease	ClinicalTrials.gov
NCT05795699	A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)	Phase 3	107		Fuchs Endothelial Corneal Dystrophy	RIPASUDIL	Its record names the disease	ClinicalTrials.gov
NCT03813056	Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy	Phase 2	72		Fuchs Endothelial Dystrophy	RIPASUDIL HYDROCHLORIDE DIHYDRATE	Its record names the disease	ClinicalTrials.gov
NCT05275972	Descemet Endothelial Thickness Comparison Trial II	Phase 3	60		Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy	RIPASUDIL	Its record names the disease	ClinicalTrials.gov
NCT06969586	The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy		50		Fuchs Endothelial Corneal Dystrophy, Cataract, Glaucoma	NETARSUDIL	Its record names the disease	ClinicalTrials.gov
NCT04440280	Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy	Phase 2	45		Fuchs Endothelial Corneal Dystrophy	ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Once Daily Netarsudil Ophthalmic Solution vs Twice Daily Netarsudil Ophthalmic Solution: deaths from any cause	0 of 20	0 of 20	40	NCT04498169	Trial comparisons
Once Daily Netarsudil Ophthalmic Solution vs Twice Daily Netarsudil Ophthalmic Solution: serious adverse events	0 of 20	1 of 20	40	NCT04498169	Trial comparisons
Netarsudil vs Placebo: deaths from any cause	0 of 15	0 of 14	29	NCT04051463	Trial comparisons
Netarsudil vs Placebo: serious adverse events	0 of 15	0 of 14	29	NCT04051463	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33737034	RESULT	1	PubMed
40789362	DERIVED	1	PubMed
39353677	DERIVED	1	PubMed
36327101	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005321

GET https://conductscience.org/api/diseases/v1/MONDO_0005321/drugs

API reference For AI assistants